Announcements & Circulars-Alphamab Oncology

English 中文简体中文繁体

English 中文简体中文繁体

Investors

Information Disclosure

Listing Documents

Financial Reports

Announcements & Circulars

Company Presentation

Corporate Governance

Stock Information

Corporate Communications

Email Subscription

Announcements & Circulars

The announcement begins in December 2019

ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023 2024-03-28
DATE OF BOARD MEETING 2024-03-18
Monthly Return of Equity Issuer on Movements in Securities for the month ended 29 February 2024 2024-03-05
Notification Letter to Registered Shareholders and Reply Form - Arrangement of Electronic Dissemination of Corporate Communications 2024-02-06
Notification Letter to Non-registered Shareholders and Reply Form - Arrangement of Electronic Dissemination of Corporate Communications 2024-02-06
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2024 2024-02-06
VOLUNTARY ANNOUNCEMENT - LICENSE AGREEMENT WITH 3D MEDICINES AND GLENMARK FOR KN035 2024-01-25
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2023 2024-01-04
EXTENSION OF WAIVER REGARDING THE QUALIFICATION AND EXPERIENCE OF A JOINT COMPANY SECRETARY 2023-12-19
VOLUNTARY ANNOUNCEMENT - A PHASE I/II CLINICAL TRIAL OF JSKN033 FOR THE TREATMENT OF HER2-EXPRESSING ADVANCED OR METASTATIC SOLID TUMORS WAS APPROVED IN AUSTRALIA 2023-12-08